SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-022902
Filing Date
2021-11-12
Accepted
2021-11-10 17:55:56
Documents
50
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgls-20210930.htm   iXBRL 10-Q 1620566
2 EX-31.1 ex-311x20210930.htm EX-31.1 9815
3 EX-31.2 ex-312x20210930.htm EX-31.2 9792
4 EX-32.1 ex-321x20210930.htm EX-32.1 9688
  Complete submission text file 0001628280-21-022902.txt   6116617

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgls-20210930.xsd EX-101.SCH 36876
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgls-20210930_cal.xml EX-101.CAL 52578
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgls-20210930_def.xml EX-101.DEF 214295
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgls-20210930_lab.xml EX-101.LAB 503625
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgls-20210930_pre.xml EX-101.PRE 313117
10 EXTRACTED XBRL INSTANCE DOCUMENT rgls-20210930_htm.xml XML 980295
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35670 | Film No.: 211398119
SIC: 2834 Pharmaceutical Preparations